SCHEMBL3725837

SCHEMBL3725837

c1ccc(/N=N/c2ccc3c(c2)Cc2cc(/N=N/c4ccccn4)ccc2-3)nc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 2/20 0.56
MAOB P27338 2/20 0.56
CYP1A2 P05177 4/20 0.52
CYP3A4 P08684 3/20 0.52
CYP2C19 P33261 3/20 0.52
CYP2C9 P11712 2/20 0.52
KDM4E B2RXH2 3/20 0.40
LMNA P02545 3/20 0.40
MAPT P10636 3/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
OPRK1 P41145 2/20 0.40
HTT P42858 2/20 0.40
NPSR1 Q6W5P4 2/20 0.40
TDP1 Q9NUW8 2/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
PKM P14618 1/20 0.40
KMT2A Q03164 1/20 0.40
ALDH1A1 P00352 3/20 0.38
NPC1 O15118 2/20 0.38
HPGD P15428 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3725841 1.00 MAOA (0.56) MAOAMAOBCYP1A2CYP3A4CYP2C19
SCHEMBL3741806 0.77 ALDH1A1 (0.50) CYP1A2CYP3A4CYP2C19CYP2C9KDM4E
SCHEMBL3741810 0.77 ALDH1A1 (0.50) CYP1A2CYP3A4CYP2C19CYP2C9KDM4E
SCHEMBL2470956 0.74 MAOA (0.77) MAOAMAOBCYP1A2KDM4ELMNA
SCHEMBL275526 0.74 MAOA (0.77) MAOAMAOBCYP1A2KDM4ELMNA
SCHEMBL29785641 0.74 MAOA (0.77) MAOAMAOBCYP1A2KDM4ELMNA
SCHEMBL27781079 0.73 MAOA (0.59) MAOAMAOBCYP2C9KDM4ELMNA
SCHEMBL6747958 0.73 MAOA (0.50) MAOAMAOBKDM4ELMNAMAPT
SCHEMBL6747962 0.73 MAOA (0.50) MAOAMAOBKDM4ELMNAMAPT
SCHEMBL670019 0.73 MAOA (1.00) MAOAMAOBKDM4ELMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7825279-B2 Fused ring dicationic anti-protozoan agents and their prodrugs THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 2010-11-02 US claimed
US-20050165044-A1 Fused ring dicationic anti-protozoan agents and their prodrugs BOYKIN DAVID W (US) 2005-07-28 US claimed
US-7825279-B2 Fused ring dicationic anti-protozoan agents and their prodrugs THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 2010-11-02 US disclosed
EP-1689705-A4 FUSED RING DICATIONIC ANTI-PROTOZOAN AGENTS AND THEIR PRODRUGS UNIV NORTH CAROLINA (US) 2007-08-29 EP disclosed
EP-1689705-A2 FUSED RING DICATIONIC ANTI-PROTOZOAN AGENTS AND THEIR PRODRUGS UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 2006-08-16 EP disclosed
US-20050165044-A1 Fused ring dicationic anti-protozoan agents and their prodrugs BOYKIN DAVID W (US) 2005-07-28 US disclosed
WO-2005051296-A2 FUSED RING DICATIONIC ANTI-PROTOZOAN AGENTS AND THEIR PRODRUGS UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 2005-06-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050165044-A1 Fused ring dicationic anti-protozoan agents and their prodrugs DHODH, DHFR, PAICS MAOA 4456/4885MAOB 3612/4885CYP1A2 342/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.